Psoriasis — SCE Dermatology MCQ

Correct answer: D — Immunogenic failure — anti-drug antibodies reducing drug levels; consider switching biologic class

The correct answer is D, immunogenic failure, anti-drug antibodies reducing drug levels, consider switching biologic class. Detectable anti-adalimumab antibodies alongside low trough drug levels demonstrate that the immune system has generated neutralising antibodies against the biologic, accelerating its clearance and reducing circulating drug exposure below the therapeutic threshold. This is the classic pattern of secondary (immunogenic) loss of response to anti-TNF monoclonal antibodies such as adalimumab, and is well recognised as more clinically significant for monoclonal antibody biologics (adalimumab, infliximab) than for fusion proteins like etanercept. Because the antibodies are directed against the adalimumab molecule itself, simply raising the dose will not overcome this and the drug will continue to be neutralised, so current UK dermatology practice is to switch to a biologic of a different mechanistic class (for example an IL-17 or IL-23 inhibitor) rather than dose escalate or swap within the same class. Why the other options are wrong: B Optimal dosing, continue unchanged: this pattern (low levels plus antibodies) is the definition of loss of response, not adequate therapeutic exposure, so continuing unchanged would perpetuate treatment failure. C Laboratory error: reproducible low trough levels with concurrently detectable anti-drug antibodies form a recognised, biologically coherent pattern rather than an isolated anomalous result, so error is not the appropriate assumption. D Pharmacokinetic failure, increase dose: pharmacokinetic failure refers to low trough levels without antibodies (for example due to rapid clearance in obesity), where dose escalation can help; here the antibodies will simply neutralise any extra drug given. E Non-adherence: non-adherence typically produces very low or undetectable drug levels without a specific antibody signature, and does not explain the presence of anti-drug antibodies, which require ongoing drug exposure to develop. Key point: low trough levels plus detectable anti-drug antibodies signifies immunogenic (antibody-mediated) failure, which is managed by switching to a different biologic class rather than increasing the dose.

Reference: British Association of Dermatologists guidelines for biologic therapy for psoriasis 2023: a pragmatic update, British Journal of Dermatology 2024;190(2):270-282, https://academic.oup.com/bjd/article/190/2/270/7280929